VentureMed Group, a Minnesota-based medical device innovator focused on vessel preparation and access management technologies for peripheral arterial disease (PAD) and arteriovenous fistulas and grafts (AVF, AVG), announced the completion of a $28 million Series C financing round. The funding was led by S3 Ventures, with participation from existing investors, including Endeavour Vision.
The new capital will accelerate the commercial adoption of VentureMed’s FLEX Vessel Prep™ (VP) System, support its clinical evidence program, and drive development of new applications in adjacent vascular settings. The FLEX system, which has FDA 510(k) clearance and CE Mark approval, is also supported by a dedicated CMS HCPCS code (C1600) with transitional pass-through payment in the U.S., positioning the company for expanded domestic and global market growth.
VentureMed’s proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology differentiates the FLEX system from traditional balloon-based approaches by using controlled motion and dynamic vessel apposition to create precise micro-incisions. This method improves vessel compliance, facilitates luminal gain, and may enhance drug uptake while reducing the risk of trauma and restenosis. The system’s design aims to address key challenges in vascular access by minimizing repeat interventions and improving long-term outcomes.
Vascular diseases represent a growing global health challenge, driven by obesity, diabetes, and hypertension. PAD affects more than 20 million people in the U.S. and over 200 million worldwide, while stenosis and vessel dysfunction continue to contribute significantly to access failure in dialysis patients. VentureMed’s FLEX VP System aims to offer a more durable and practical approach to vessel preparation, aligning with the healthcare industry’s shift toward value-based care models.
KEY QUOTES:
“As we enter our next phase, we are grateful for the continued support of our existing investors and excited to welcome new partners to the syndicate. This significant financing underscores investor confidence in the FLEX Vessel Prep™ System and our mission to strengthen VentureMed’s position in global vascular care.”
Denis Harrington, President and CEO, VentureMed Group
“VentureMed is addressing one of the most persistent challenges in vascular access with a technology that is both elegant and transformative. Our partnership reflects a shared mission to bring breakthrough treatments to those who need them most.”
Brian R. Smith, Managing Director, S3 Ventures
“Lesion prep is rapidly becoming one of the most important procedures for improving patient outcomes. The FLEX VP system is leading the way in addressing AV Access interventions. This fundraising is an important milestone as the company advances additional clinical evidence and expanded indications.”
Dr. Ari Kramer, General Surgeon, Spartanburg Medical Center
“The cycle of re-narrowing and repeat procedures in vascular disease places a significant burden on patients and health systems. A technology that reduces the need for reinterventions not only improves outcomes but also aligns with the shift to value-based care. We’re excited to continue supporting VentureMed as it expands access to this important therapy.”
Alexander Schmitz, Partner, Endeavour Vision
